Endometrial cancer care is increasingly shaped by molecular information, making biomarker testing an essential part of treatment planning for patients with advanced or recurrent disease. In this episode of Inside the Lab, host Dr. Ali Brown, CEO of the American Society for Clinical Pathology, speaks with Dr. Casey Cosgrove, a gynecologic oncologist at The Ohio State University, and Dr. Meg Dibbern, a breast and gynecologic pathologist at Emory University, about how biomarkers including MMR/MSI, POLE, p53, and HER2 can help define tumor biology, inform prognosis, and guide systemic treatment decisions.
The guests explore how testing across immunohistochemistry, PCR, and next-generation sequencing fits into real-world laboratory workflows and how pathology and oncology teams can work together to ensure results are comprehensive, timely, and actionable. The discussion also considers the challenges of translating evolving clinical guidelines into practice and the importance of communication between the laboratory, clinicians, and patients as treatment options continue to expand.
Course topics include:
- Molecular Classification of Endometrial Cancer
- Biomarker Testing and Systemic Treatment Selection
- Pathology–Oncology Collaboration in Biomarker Testing
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Learning Objectives
Upon completion of this activity, you will be able to:
- Describe the roles of MMR/MSI, POLE, p53, and HER2 testing in the molecular classification, prognostic assessment, and treatment of endometrial cancer.
- Explain how biomarker results can inform systemic treatment planning for patients with advanced or recurrent endometrial cancer, including the selection of immunotherapies and targeted therapies.
- Identify strategies for improving communication and collaboration between pathology and oncology teams to support timely, comprehensive, and clinically actionable biomarker testing.
Faculty
Megan Dibbern, MD
Assistant Professor of Pathology & Laboratory Medicine
Assistant Director of Pathology Residency Training Program
Resident Rotation Director, Cytopathology
Emory University Hospital/Emory University Hospital Midtown
Atlanta, Georgia
Casey Cosgrove, MD
Associate Professor and Gynecologic Oncologist
The Ohio State University / James Cancer Hospital
Columbus, Ohio
Faculty Disclosures
All financial relationships for Casey Cosgrove have been mitigated. Megan Dibbern has no financial relationships to disclose.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of 1.0 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of Participation
To complete the activity and receive credit, the participant must participate in the activity. CME certificates will be provided online.
Commercial Support
This activity is supported by an independent educational grant from Merck.